OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
55
Results
Show all
Save search
Copy query
Show results for
Unknown
(55)
Publication Date
Release Date
2018
(6)
2014
(6)
2020
(5)
2016
(5)
2025
(4)
2022
(4)
2017
(4)
2013
(4)
2012
(4)
2023
(3)
2019
(3)
2021
(2)
2010
(2)
2026
(1)
2015
(1)
2011
(1)
Previous
page
1 / 6
You're on page
1
page
2
page
3
page
4
page
5
page
6
Next
page
Sort
by:
Relevance
Page size
10
Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.
Not available
S-EPMC5950499
|
biostudies-literature
Cite
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
Not available
S-EPMC5950497
|
biostudies-literature
Cite
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Not available
S-EPMC5791843
|
biostudies-literature
Cite
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
Not available
S-EPMC4966513
|
biostudies-literature
Cite
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.
Not available
S-EPMC5042214
|
biostudies-literature
Cite
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
Not available
S-EPMC4171358
|
biostudies-literature
Cite
Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results.
Not available
S-EPMC4245073
|
biostudies-literature
Cite
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma.
Not available
S-EPMC4872006
|
biostudies-literature
Cite
Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma.
Not available
S-EPMC5278973
|
biostudies-literature
Cite
R-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repair.
Not available
S-EPMC3224749
|
biostudies-literature
Cite
Previous
page
1 / 6
You're on page
1
page
2
page
3
page
4
page
5
page
6
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets